Navigation Links
iCo Therapeutics Closes $1.3 Million Private Placement
Date:2/9/2009

acement. All securities issued in the private placement are subject to a four month hold period. The private placement is subject to regulatory approval, including the approval of the TSX Venture Exchange.

About iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products, iCo-007, in Phase I for the treatment of Diabetic Macular Edema, iCo-008, a product with Phase II clinical history to be developed for severe ocular allergies, and iCo-009, an oral formulation of Amphotericin B for sight and life - threatening diseases. iCo-009 also represents a new drug delivery technology with the potential to reprofile other parenteral administered drugs to the oral route of administration. iCo Therapeutics trades on the TSX-Venture exchange under the symbol "ICO". For more information, visit the company website at: www.icotherapeutics.com

    No regulatory authority has approved or disapproved the content of this
    release. The TSX Venture Exchange does not accept responsibility for the
    adequacy or accuracy of this release.

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics' current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial per
'/>"/>

SOURCE iCo Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
2. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
3. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
4. Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share
5. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
6. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
7. Omnitura Therapeutics Announces Private Placement Financing
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
10. CV Therapeutics Statement on Unsolicited Proposal From Astellas
11. Cell Therapeutics Receives Additional NASDAQ Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 DuPont Pioneer announced today that ... president of Agricultural Biotechnology (ABT), effective July 21, 2014. ... most recently as president, chief executive officer and board ... in the seed and crop protection industry to this ... Schickler , president of DuPont Pioneer. “I am looking ...
(Date:7/23/2014)... BRUSSELS , July 23, 2014 regulated ... its research and development pipeline with positive topline ... brivaracetam . This study was designed to evaluate ... (100 and 200 mg/day, without titration) compared to ... patients with partial-onset seizures, not fully controlled despite ...
(Date:7/23/2014)... 23, 2014  GrowBLOX Sciences, Inc. (OTCQB: GBLX), a medical ... filing for two medical marijuana dispensary locations in ... to the Clark County, Nevada dispensary ... as previously announced.  GrowBLOX Sciences, CEO Craig ... new applications for dispensaries in the City of ...
(Date:7/23/2014)... China Cord Blood Corporation (NYSE: CO ) ("CCBC" or ... blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell ... catering to the mother and child segment, today announced that the ... Singapore , Hong Kong , ... the Philippines and Malaysia ...
Breaking Biology Technology:DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4
... Mass., Oct. 10 Targanta,Therapeutics Corporation (Nasdaq: TARG ... of 5,750,000 shares of its common stock at a ... the shares are being offered by,Targanta. Targanta has granted ... an additional 862,500 shares of common stock at the ...
... Signalife has received,additional sales orders in excess of ... Lowell Harmison,s most recent cross-country sales,initiative. These purchase orders ... the company anticipates achieving break-even status,by the end of ... of 2008 first,quarter. About Signalife: Signalife, Inc. ...
... 10 DermTech International, Inc.,a biotechnology company ... of melanoma and other diseases, today appointed ... Board. Dr. Quackenbush is a,Professor of Biostatistics ... and Professor of Computational Biology and Bioinformatics,at ...
Cached Biology Technology:Targanta Therapeutics Announces Pricing of its Initial Public Offering 2Signalife Continues to Procure Purchase Orders, Revenues 2DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Company's Scientific Advisory Board 2
(Date:7/24/2014)... gut that has gone undetected by scientists for decades. ... State University has found that more than half the ... named crAssphage, which infects one of the most common ... of bacteria is thought to be connected with obesity, ... in Nature Communications ., Robert A. Edwards, a ...
(Date:7/23/2014)... or neglected early in life are at risk ... In a new study, scientists have found that ... has implications for children,s long-term development. Previous studies ... and genetics interacted with that child,s experiences in ... In the new study, researchers were able to ...
(Date:7/23/2014)... of Defense recently awarded the STEMPREP Project at ... support its goal of increasing the number of ... minority middle school students for the two-summer classroom ... school students with summer opportunities at research labs. ... Simmons School of Education and Human Development, boasts ...
Breaking Biology News(10 mins):Newly discovered gut virus lives in half the world's population 2Newly discovered gut virus lives in half the world's population 3Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3Department of Defense awards $2.6 million grant to SMU STEM program for minority students 2
... NY, June 27, 2011Sophisticated genetic tools and techniques for ... in bone marrow will drive the successful application of ... Examples of these cutting-edge methods are presented in a ... of Human Gene Therapy , a peer-reviewed journal ...
... A team of researchers from the National Institute ... and the University of Maryland has made nano-sized ... from paints, cleaners, pesticides and other productsthat offer ... low-power room-temperature operation and the ability to detect ...
... Most previous studies have indicated that people in cities have ... country. By using more complex methods of analysis than in ... that people,s carbon emissions are practically the same in the ... CO 2 emissions that cause climate change are dependent ...
Cached Biology News:The promise of stem cell-based gene therapy 2Nanowire-based sensors offer improved detection of volatile organic compounds 2City dwellers produce as much CO2 as countryside people do 2
... MasterAmp™ Taq DNA Polymerase is a ... aquaticus. Having optimal activity at temperatures ... thermostable enzyme used for PCR and ... purpose. The enzyme has an intrinsic ...
... 4100 high pressure dual piston pump and the ... and utra low drift. The WaveQuest ... detection and provides superior stability. Hence ... and for monitoring to the highest of sensitivities. ...
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
Biology Products: